Payment overview · 2025
General Payments
$647.75
31 reported records · 13 companies
Healthcare provider profile · identity verified
Derek Almendares, DO
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI LAKES, FL · NPI 1144885526
Verified facts
What the public records show
CMS Open Payments records show Derek Almendares, DO received $647.75 in general payments during 2025 across 31 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $202.10 | 31.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.97 | 23.0% | 11 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $69.61 | 10.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.67 | 6.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.35 | 5.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.47 | 4.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.61 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.82 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.38 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.24 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.62 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.53 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.38 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $647.75 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $202.10 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $122.78 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $110.20 | 9 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $69.61 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 131 |
| Gabapentin | Gabapentin | 290 | 61 |
| Metformin Hcl | Metformin Hcl | 244 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 44 |
| Lisinopril | Lisinopril | 211 | 46 |
| Famotidine | Famotidine | 209 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 43 |
| Losartan Potassium | Losartan Potassium | 198 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 185 | 52 |
| Carvedilol | Carvedilol | 184 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 55 |
| Omeprazole | Omeprazole | 154 | 44 |
| Furosemide | Furosemide | 144 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 39 |
| Eliquis | Apixaban | 127 | 31 |
| Azithromycin | Azithromycin | 126 | 79 |
| Methylprednisolone | Methylprednisolone | 123 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 28 |
| Montelukast Sodium | Montelukast Sodium | 105 | 23 |
| Chlorthalidone | Chlorthalidone | 102 | 23 |
| Spironolactone | Spironolactone | 98 | 17 |
| Ozempic | Semaglutide | 97 | 16 |
| Memantine Hcl | Memantine Hcl | 89 | 19 |
| Glimepiride | Glimepiride | 85 | 19 |
| Ketoconazole | Ketoconazole | 83 | 19 |
| Mounjaro | Tirzepatide | 83 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 22 |
| Entresto | Sacubitril/Valsartan | 68 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 28 |
| Naproxen | Naproxen | 67 | 41 |
| Allopurinol | Allopurinol | 66 | 11 |
| Metformin Hcl Er | Metformin Hcl | 65 | 14 |
| Prednisone | Prednisone | 64 | 24 |
| Xarelto | Rivaroxaban | 62 | 16 |
| Alprazolam | Alprazolam | 61 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 17 |
| Clonidine Hcl | Clonidine Hcl | 60 | 13 |
| Jardiance | Empagliflozin | 60 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 21 |
| Nifedipine Er | Nifedipine | 59 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 40 |
| Baclofen | Baclofen | 51 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 15 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Ciclopirox | Ciclopirox | 46 | 11 |
| Farxiga | Dapagliflozin Propanediol | 46 | 11 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Torsemide | Torsemide | 43 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 22 |
| Linzess | Linaclotide | 41 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 39 | suppressed |
| Brilinta | Ticagrelor | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 11 |
| Topiramate | Topiramate | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 12 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Benzonatate | Benzonatate | 26 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 18 |
| Finasteride | Finasteride | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | 16 |
| Glipizide | Glipizide | 25 | suppressed |
| Ofloxacin | Ofloxacin | 25 | 19 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 12 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $647.75 · 31 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, FREESTYLE LIBRE, FUROSCIX, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Omnipod, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error